Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Mallinckrodt
Daiichi Sankyo
US Department of Justice
Chinese Patent Office
UBS
Covington
Boehringer Ingelheim

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,503,894

« Back to Dashboard

Which drugs does patent 6,503,894 protect, and when does it expire?

Patent 6,503,894 protects ANDROGEL and is included in two NDAs.

Protection for ANDROGEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and nine patent family members in thirty-one countries.
Summary for Patent: 6,503,894
Title: Pharmaceutical composition and method for treating hypogonadism
Abstract:A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.
Inventor(s): Dudley; Robert E. (Kenilworth, IL), Kottayil; S. George (Long Grove, IL), Palatchi; Olivier (L'Hay les Roses, FR)
Assignee: Unimed Pharmaceuticals, Inc. (Marietta, GA) Laboratories Besins Iscovesco (Herndon, VA)
Application Number:09/651,777
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,503,894
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Drugs Protected by US Patent 6,503,894

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 021015-003 Sep 26, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-002 Sep 7, 2012 AB2 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 AB2 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,503,894

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,004,092,494 ➤ Sign Up
9,132,089 Pharmaceutical composition and method for treating hypogonadism ➤ Sign Up
9,125,816 Pharmaceutical composition and method for treating hypogonadism ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
UBS
Argus Health
Daiichi Sankyo
Johnson and Johnson
Citi
Chinese Patent Office
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.